Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

Anemia of chronic kidney disease: Treat it, but not too aggressively

Georges Nakhoul, MD and James F. Simon, MD
Cleveland Clinic Journal of Medicine August 2016, 83 (8) 613-624; DOI: https://doi.org/10.3949/ccjm.83a.15065
Georges Nakhoul
Department of Nephrology and Hypertension, Glickman Urological and Kidney institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James F. Simon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1
  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Iron absorption and metabolism is controlled by several proteins.

    DMT1 = divalent metal transporter 1; FPN = ferroportin; Hgb = hemoglobin; TF = transferrin, TFR = transferrin receptor

Tables

  • Figures
    • View popup
    TABLE 1

    Four randomized controlled trials of hemoglobin-raising in chronic kidney disease

    NHCT52CHOIR53CREATE54TREAT55
    PopulationPatients with chronic heart failure and end-stage renal disease on dialysisChronic kidney diseaseChronic kidney diseaseChronic kidney disease with diabetes
    Hemoglobin target10 vs 14 g/dL13.5 vs 11.3 g/dL> 13 vs 11 g/dL> 13 vs 9 g/dL
    Target achieved?NoNoYesNo
    Primary outcomesTime to death or first myocardial infarctionComposite of death, myocardial infarction, hospitalization for chronic heart failure, strokeTime to first cardiovascular eventComposite of death or a cardiovascular event and death or end-stage renal disease
    Risks with higher hemoglobin levelTrend toward increased risk of primary outcome resulted in early study interruptionIncreased risk of primary outcomeTrend toward risk increase that was nonsignificant: no benefitsNo risk increase or reduction
    Other resultsHigher rate of thrombosis in high-target groupImproved quality of lifeHigher rate of stroke
    • NHCT = Normal Hematocrit Study,52 CHOIR = Correction of Hemoglobin and Outcomes in Renal Insufficiency trial,53 CREATE = Cardiovascular Risk Reduction by Early Anemia Treatment trial,54 TREAT = Trial to Reduce Cardiovascular Events With Aranesp Therapy55

    • View popup
    TABLE 2

    Target hemoglobin and iron indices

    Target hemoglobinTarget ferritinTarget transferrin saturation
    Chronic kidney disease> 10 g/dL> 100 ng/mL> 20%
    End-stage renal disease10–11.5 g/dL200–1,200 ng/mL30%–50%
    • Based on information in KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2:279–335.

    • View popup
    TABLE 3

    Erythropoiesis-stimulating agent hyporesponsiveness: A practical approach

    CauseTestCourse of action
    Easily correctable causesx
    Iron deficiencyIron studiesIf low, replenish
    Vitamin B12 deficiencyVitamin B12 levelIf low, replenish
    Folate deficiencyFolate levelIf low, replenish
    HypothyroidismThyroid-stimulating hormone levelManage hypothyroidism
    ACEi/ARB-induced anemiaACEi or ARB levelStop ACEi or ARB
    Potentially correctable causes
    Infection and inflammationSerum C-reactive protein levelIf elevated, check for and treat infection or inflammation
    HyperparathyroidismParathyroid hormone levelManage hyperparathyroidism
    UnderdialysisKt/VImprove dialysis efficiency
    Blood loss or hemolysisReticulocyte count (look for high value)Endoscopy, colonoscopy, hemolysis screen
    Bone marrow disorder, pure red-cell aplasiaReticulocyte count (look for low value)Check anti-ESA antibodies, parvovirus polymerase chain reaction, consider bone marrow biopsy
    Noncorrectable causes
    HemoglobinopathiesSerum protein electrophoresisHematology referral
    Bone marrow disordersBone marrow biopsyHematology referral
    • ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker, Kt/V = dialyzer clearance of urea times dialysis time, divided by volume of distribution of urea

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 83 (8)
Cleveland Clinic Journal of Medicine
Vol. 83, Issue 8
1 Aug 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anemia of chronic kidney disease: Treat it, but not too aggressively
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anemia of chronic kidney disease: Treat it, but not too aggressively
Georges Nakhoul, James F. Simon
Cleveland Clinic Journal of Medicine Aug 2016, 83 (8) 613-624; DOI: 10.3949/ccjm.83a.15065

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Anemia of chronic kidney disease: Treat it, but not too aggressively
Georges Nakhoul, James F. Simon
Cleveland Clinic Journal of Medicine Aug 2016, 83 (8) 613-624; DOI: 10.3949/ccjm.83a.15065
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • DEFINITION AND PREVALENCE
    • RENAL ANEMIA IS ASSOCIATED WITH BAD OUTCOMES
    • RENAL ANEMIA IS MULTIFACTORIAL
    • ERYTHROPOIETIN, IRON, AND RED BLOOD CELLS
    • TREATMENT OF RENAL ANEMIA
    • PARTICULAR CIRCUMSTANCES
    • ANEMIA IN CANCER PATIENTS
    • NOVEL TREATMENTS
    • TAKE-HOME POINTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Anemia of chronic kidney disease (August 2016)
  • PubMed
  • Google Scholar

Cited By...

  • Anemia of chronic kidney disease: Will new agents deliver on their promise?
  • Chronic kidney disease in low-income to middle-income countries: the case for increased screening
  • Google Scholar

More in this TOC Section

  • High-output heart failure from arteriovenous dialysis access: A structured approach to diagnosis and management
  • Direct oral anticoagulants: Challenging prescribing scenarios in everyday practice
  • IgA nephropathy: Update on pathogenesis and treatment
Show more Review

Similar Articles

Subjects

  • Drug Therapy
  • Hematology
  • Nephrology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire